Condition: Acute Myocardial Infarction · Cardiogenic Shock · Sponsor: Assistance Publique - Hôpitaux de Paris
Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days). An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of the experimental treatment arm.
This description comes directly from the study's public registry record.
Alain COMBES, MD, PhD · 01.42.16.38.16 · alain.combes@aphp.fr
Gilles MONTALESCOT, MD, PhD · 01.42.16.30.07 · gilles.montalescot@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital Pitié Salpétrière | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04184635